TX-PLANVIEW
22.6.2022 19:03:04 CEST | Business Wire | Press release
Planview ®, the global leader in Portfolio Management and Work Management, today announced the acquisition of Enrich , a product portfolio analytics company that empowers R&D organizations with complex portfolios to make strategic business decisions in real-time.
"As product portfolios continue to expand, companies are making big bets on business initiatives that can cost millions of dollars and take years to see to completion,” said Razat Gaurav, Chief Executive Officer at Planview. “Enrich brings deep expertise in complex product prioritization and data science techniques supporting portfolio decision-making, allowing companies to make more confident and insight-driven decisions on the investments that will achieve the greatest impact.”
“Enrich and Planview share a similar commitment: enabling our customers to achieve their most critical outcomes,” said Dr. Rich Sonnenblick, Founder and Chief Executive Officer at Enrich. “Over the last 24 years, we’ve worked with more than half of the leading life sciences companies globally to provide real-time visibility into the current and future health of their product pipelines, allowing them to make better investment decisions and align with business goals. We are looking forward to joining the Planview team and bringing our best-in-class simulation and analytics capabilities to Planview customers.”
Founded by Sonnenblick following his PhD from Carnegie Mellon University, Enrich provides a secure, cloud-based platform for portfolio prioritization, valuation, and scenario analysis using a tailored and flexible analytics engine seamlessly connected to a flexible visualization layer. The company’s emphasis is on establishing best-in-class, self-sufficient, strategic portfolio capabilities in every customer they work with.
Enrich’s Sonnenblick and his team of data scientists will join Planview, further deepening Planview’s data science and analytics expertise. Sonnenblick will serve as Planview’s Chief Data Scientist, focused on building and expanding the company’s data science initiatives and delivering predictive and prescriptive insights for Planview solutions.
Combining Enrich with Planview deepens the company’s commitment to product portfolio management and helping customers realize the future of connected work to accelerate the achievement of what matters most.
This acquisition closely follows the company’s announcement of its intent to acquire Tasktop , which is expected to close in Q3 of 2022.
About Planview
Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,000 employees supporting 4,000 customers and 2.4 million users worldwide. For more information, visit www.planview.com .
About Enrich Consulting
Founded in 1998, Enrich provides flexible analytics, scenario planning, simulation, and optimization techniques tailored for R&D teams to enable portfolio planning and prioritization, decision support, and risk analysis for highly-complex product portfolios. Leading Pharmaceutical and Life Sciences brands, including half of the top 20 life sciences companies, use Enrich to provide real-time visibility into the health of product portfolios, allowing them to make better decisions and align with business goals. For more information, visit: https://www.enrichconsulting.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621006173/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients27.4.2026 13:43:00 CEST | Press release
For Trade and Medical Media Only The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 Study showed favourable benefit for toxicity-related discontinuations and drug-drug interactions (DDIs) Rezafungin was well tolerated, with a safety profile comparable to standard antimicrobial regimens (SARs) Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing a
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 13:00:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415938477/en/ Photo credit: Jos Schmid, Photographer
tesa Selects Kinaxis as the Digital Backbone for Global Integrated Business Planning Transformation27.4.2026 13:00:00 CEST | Press release
Kinaxis Maestro™ platform to serve as the foundation for a multi‑year transformation to resilient, globally orchestrated planning ecosystem Kinaxis® (TSX: KXS), a global leader in end‑to‑end supply chain orchestration, today announced that tesa SE, a global manufacturer of adhesive tapes and self-adhesive product solutions, has selected the Kinaxis Maestro™ platform as a core enabler of its global, multi‑year supply chain and integrated business planning (IBP) transformation. Following an extensive evaluation, tesa selected Kinaxis to support its evolution from regionally fragmented planning practices toward a centrally governed, globally orchestrated IBP operatingmodel. Kinaxis will support tesa in improving enterprise-wide transparency, strengthening resilience, and enabling faster, more informed decision making across an increasingly complex and volatile global supply chain network. With 130 years of innovation, tesa is one of the world’s leading manufacturers of adhesive tapes and
70% of Enterprise AI is Uncontrolled, Driving Hidden Risk, Cost and Slower ROI27.4.2026 10:00:00 CEST | Press release
Lenovo research highlights a growing AI execution gap as organizations struggle to control and operate AI across their environments AI is already being used across your organization, whether it has been formally approved or not. Employees are using AI with or without IT involvement, fueling the rise of ‘shadow AI’ across the enterprise, creating gaps in governance and control. This is no longer just an IT challenge. For Chief Information Security Officers, this shift is expanding the attack surface across devices, endpoints, and data flows, introducing unmanaged risk and increasing the likelihood of sensitive company data being exposed or accessed without proper controls. What this reveals is a growing AI execution gap: usage is accelerating, but control is not keeping pace. Based on a survey of 6,000 employees worldwide, Lenovo’s latest Work Reborn Report, Leading Your Workforce to Triumph with AI, finds that more than 70% of employees are using AI weekly, with up to one third operati
First Enterprise Quantum Computer Purchase in Japan: IQM to Deploy System to TOYO Corporation27.4.2026 08:00:00 CEST | Press release
First enterprise quantum computer purchase in Japan cements IQM's position as the global leader in deployed quantum computers The Radiance 20-qubit system will enable TOYO to explore various industry use cases, while advancing a hybrid quantum-HPC infrastructure. This will be the third quantum computer to be deployed by IQM in the Asia-Pacific region. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the purchase of its full-stack 20-qubit quantum computer by TOYO Corporation, marking the first enterprise quantum system deployment in Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426053944/en/ (From Left): Toshiya Kohno, Representative Director, President and CEO of TOYO Corporation, and Jan Goetz, CEO & Co-founder of IQM Quantum Computers. The Radiance 20-qubit system will be made available in both on-premises and cloud environments and will be delivered by the end of 2
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom